One of the greatest challenges in treating acute myeloid leukemia (AML) is chemotherapy refractory disease. Previously, we demonstrated a novel mechanism whereby AML-induced endothelial cell (EC) activation leads to subsequent leukemia cell adherence, quiescence and chemoresistance, identifying activated ECs as
Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease
Lim MA, et al.
The Journal of Neuroscience, 32(3), 1123-1141 (2012)
JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models
Ploia C, et al.
Journal of Alzheimer'S Disease, 26(2), 315-329 (2011)
The Journal of biological chemistry, 285(35), 27449-27456 (2010-06-23)
Pathological forms of left ventricular hypertrophy (LVH) often progress to heart failure. Specific transcription factors have been identified that activate the gene program to induce pathological forms of LVH. It is likely that apart from activating transcriptional inducers of LVH
Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elderly patients with relapsed or refractory acute myeloid leukaemia (AML). We aimed to compare two dosing regimens of tosedostat. In this randomised phase
DNA damage and repair mechanism is vital for maintaining DNA integrity. Damage to cellular DNA is involved in mutagenesis, the development of cancer among others.